<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" dms-id="H9F72B09C31B04CE2BA00B47FF524020F" public-private="public" key="H" bill-type="olc">
<metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>116 HR 3223 IH: Pharmacy Benefit Manager Accountability Study Act of 2019</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2019-06-12</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code>
<congress display="yes">116th CONGRESS</congress><session display="yes">1st Session</session>
<legis-num display="yes">H. R. 3223</legis-num>
<current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber>
<action display="yes">
<action-date date="20190612">June 12, 2019</action-date>
<action-desc><sponsor name-id="M001198">Mr. Marshall</sponsor> (for himself, <cosponsor name-id="W000800">Mr. Welch</cosponsor>, <cosponsor name-id="C001103">Mr. Carter of Georgia</cosponsor>, and <cosponsor name-id="G000581">Mr. Gonzalez of Texas</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name></action-desc>
</action>
<legis-type>A BILL</legis-type>
<official-title display="yes">To require the Comptroller General of the United States to study the role pharmacy benefit managers play in the pharmaceutical supply chain and to provide Congress with appropriate policy recommendations, and for other purposes.</official-title>
</form>
<legis-body id="H0F74560382374ADB90268DBAF4FCB493" style="OLC"> 
<section id="H957C1200972F483C872B1B415E96312D" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Pharmacy Benefit Manager Accountability Study Act of 2019</short-title></quote>.</text></section> <section id="HA7AE4C9AD7B941D1A20C97A37DDECA23"><enum>2.</enum><header>Study by Comptroller General of United States</header> <subsection id="H5120E66EB73E481EA6341004DF8FBA9A"><enum>(a)</enum><header>In general</header><text display-inline="yes-display-inline">The Comptroller General of the United States shall, in consultation with appropriate stakeholders, conduct a study on the role of pharmacy benefit managers with respect to federally facilitated Exchanges operated pursuant to section 1321(c) of the Patient Protection and Affordable Care Act (<external-xref legal-doc="usc" parsable-cite="usc/42/18041">42 U.S.C. 18041(c)</external-xref>).</text></subsection> 
<subsection id="HB1554AE3E7634EFD981F25155D35E2FF"><enum>(b)</enum><header>Permissible examination</header><text display-inline="yes-display-inline">In conducting the study required under subsection (a), the Comptroller General may examine various qualitative and quantitative aspects of the role of pharmacy benefit managers with respect to federally facilitated Exchanges described in such subsection, such as the following:</text> <paragraph id="HBCA4F93F9D144DA4BC6041F39171C7C7" display-inline="no-display-inline"><enum>(1)</enum><text>The role that pharmacy benefit managers play in the pharmaceutical supply chain of such Exchanges.</text></paragraph> 
<paragraph id="H4DF33D8D60CF4881B70691A5130E51CD"><enum>(2)</enum><text>The state of competition among pharmacy benefit managers on such Exchanges, including the market share for the Nation’s largest pharmacy benefit managers.</text></paragraph> <paragraph id="H7E4D072089C44ACEB2134CA400C67FE7" commented="no"><enum>(3)</enum><text>The use of rebates and fees by pharmacy benefit managers with respect to such Exchanges, including—</text> 
<subparagraph id="H5E8FB7EF9112423E9B23DFFB70305F8E" commented="no"><enum>(A)</enum><text>the extent to which rebates are passed on to qualified health plans offered on such Exchanges and whether such rebates are passed on to individuals enrolled in such plans;</text></subparagraph> <subparagraph id="HE3B13D603FDE409381878F0B867784CA" commented="no"><enum>(B)</enum><text>the extent to which rebates are kept by such pharmacy benefit managers; and</text></subparagraph> 
<subparagraph id="H404A5B891D9446AEB293235D6295AE27" commented="no"><enum>(C)</enum><text>the role of any fees charged by such pharmacy benefit managers.</text></subparagraph></paragraph> <paragraph id="H0A117A90EA6649E2932EBF07DE799A4D"><enum>(4)</enum><text>Whether pharmacy benefit managers structure their formularies with respect to such Exchanges in favor of high-rebate prescription drugs over lower-cost, lower-rebate alternatives.</text></paragraph> 
<paragraph id="HFB886FAEA15E4126B49A15EFB01F2B44"><enum>(5)</enum><text>The average prior authorization approval time for pharmacy benefit managers with respect to such Exchanges.</text></paragraph> <paragraph id="HBAB3D5C1839A47B98E37A528CEEC1376"><enum>(6)</enum><text>Factors affecting the use of step therapy by pharmacy benefit managers with respect to such Exchanges.</text></paragraph> 
<paragraph id="HAC7543B3D9964025911C1CAB7F425040"><enum>(7)</enum><text>The extent to which the price that pharmacy benefit managers charge private payors on such Exchanges for a drug is more than such pharmacy benefit managers pay the pharmacy for the drug.</text></paragraph></subsection> <subsection id="H1C11968A958A49FEA9A6D6BC97FA794B"><enum>(c)</enum><header>Report</header><text display-inline="yes-display-inline">Not later than the date that is three years after the date of enactment of this Act, the Comptroller General shall submit to the Secretary of Health and Human Services, the Committee on Health, Education, Labor, and Pensions of the Senate, and the Committee on Energy and Commerce of the House of Representatives a report containing the results of the study conducted under subsection (a), including policy recommendations.</text></subsection></section> 
</legis-body>
</bill> 


